Remove Heart Failure Remove Reimbursement Remove Technology
article thumbnail

BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

DAIC

CMS has reviewed the CardiAMP Heart Failure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage. The CardiAMP Heart Failure II Trial is FDA approved to enroll up to 250 patients at up to 40 clinical centers. said Peter Altman , PhD.,

CMS 111
article thumbnail

Biocardia Reports Positive Interim Results from Phase III Cardiamp Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure

DAIC

Results showed reductions in heart death equivalents and MACCE, with a magnified reduction among patients with elevated NTproBNP, a common marker of heart distress. These patients saw more than a 17% lower rate of heart death equivalents at up to two years compared to control patients treated with heart failure medication alone (2.9%

article thumbnail

CVRx Announces Key Senior Leadership Team Hires

DAIC

Adamson, MD, MSc, FACC, FESC, FRCP (Ed ) has been appointed as Chief Medical Officer, Bonnie Handke, RN, MBA will assume the role of Senior Vice President of Patient Access, Reimbursement, and Healthcare Economics, and Jennifer E. Englund recently joined as Senior Vice President of Global Clinical Affairs. Handke earned an MBA from St.

article thumbnail

American College of Cardiology, ACC, Releases Guide to Remote Patient Management

DAIC

In its announcement about the workbook, ACC noted that cardiologists use digital devices and wearable technology to remotely monitor their patients for a variety of chronic cardiovascular diseases, including heart failure, coronary artery disease, vascular disease and atrial fibrillation.

article thumbnail

Cardiac Dimensions Appoints Satya Shreenivas, MD, as Chief Medical Officer

DAIC

There, he served as an investigator in many high-profile clinical trials, including several significant structural heart studies. Dr. Shreenivas is a frequent speaker at major scientific meetings and has been widely published in peer-reviewed journals across the structural heart, heart failure, and coronary arenas.

article thumbnail

Supercharging the ECG: AI set to Revolutionize the Diagnostic Cardiology Market

DAIC

Inevitably, given its fledgling status, regulation and reimbursement is still playing catch-up, though 2023 saw some important developments in this regard. By 1909 ECGs were being used to diagnose cases of arrhythmia; by 1910 to diagnose indicators of a heart attack.

AFIB 105
article thumbnail

Cost?effectiveness analysis of leadless cardiac resynchronization therapy

Journal of Cardiovascular Electrophysiology

Advancements in battery technology will be beneficial in improving the treatment's economic profile. Abstract Background The Wireless Stimulation Endocardially for CRT (WiSE-CRT) system is a novel technology used to treat patients with dyssynchronous heart failure (HF) by providing leadless cardiac resynchronization therapy (CRT).